Newron to resubmit acquisition of Swedish neurogenesis company NeuroNova AB to its shareholders 31/10/2012[2].pdf

Stem Cell is pleased to announce this involvement with CCRM as well as the receipt of US$175,000   a $250,000 arrangement with a Swedish private company developing new therapeutics for ALS and Parkinson's. The full payment will settle a patent interference case initiated by the United States Patent and Trademark Office under which Stem Cell has withdrawn certain pending and issued patents to treat Parkinson's disease. 29/10/2012

About Newron


Newron Pharmaceuticals S.p.A. ( is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. Phase III trials of safinamide are currently ongoing for the treatment of Parkinson's disease (PD). As per the agreement signed with Newron in 2006, Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has exclusive worldwide rights to develop, manufacture and commercialize the compound in PD, Alzheimer's disease, and other therapeutic applications.

Newron is currently evaluating the further clinical development of ralfinamide for pain and psychiatric diseases. Newron-s additional projects are at various stages of preclinical and clinical development, including HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases.

 Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SIX Swiss Exchange, trading symbol NWRN.